Cumulus Neuroscience, a global digital health company dedicated to transforming neuroscience clinical trials and patient care through advanced data-driven solutions, has appointed Robert Ballantine to its Board of Directors.
Cumulus is widely recognized for its pioneering NeuLogiq® Platform, developed in collaboration with 10 of the world’s leading pharmaceutical companies. The platform enables continuous tracking of brain function both in clinical settings and remotely from a participant’s home. Using a tablet, study participants engage in gamified versions of established behavioral tasks while wearing the NeuLogiq® headset.
The device records EEG (electroencephalogram) brain waves that are precisely time-synced with task performance, delivering biopharma companies deeper, more accurate insights into brain network activity. This innovative approach has the potential to accelerate clinical research and improve treatment outcomes in neurological disorders.
Mr. Ballantine currently serves as Managing Principal of Integrated Digital Health at IQVIA, a role he has held since July 2022. He brings over 25 years of expertise in digital innovation, human-centered design, and program leadership, with the past 15 years dedicated to advancing life sciences.
His extensive background in designing and deploying patient-centric digital health solutions will bring valuable perspective to Cumulus as the Company continues to expand the reach and impact of its technologies.
Ballantine holds a Bachelor’s degree in Behavioural Science and a Master’s in Ergonomics. His appointment underscores Cumulus Neuroscience’s commitment to strengthening its leadership as it drives forward the future of neuroscience research and patient care.
